Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
This conversation was a satire post about hair loss treatments, and included a range of different treatments from biotin to handstands. Finasteride and Minoxidil were specifically mentioned as potential treatments that have scientific evidence to support their effectiveness.
The user is considering another hair transplant or scalp micropigmentation (SMP) for a congenital bald spot, but previous transplants were less effective due to scar tissue. Suggestions include using hair fibers, changing hairstyles, or doing nothing, as the spot is not very noticeable.
A 40+ year old is regrowing their hairline using microneedling, minoxidil, tretinoin, low-level laser therapy, massages, and Nizoral, without using finasteride or dutasteride. They noted progress in hair growth below a birthmark, an area that hadn't seen growth since their teenage years.
The conversation is about using finasteride and testosterone replacement therapy (TRT) for hair loss and their role in gender-affirming care. It debates whether these treatments are considered hormone replacement therapy (HRT) and their implications for both cisgender and transgender individuals.
A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
Hair loss treatments, specifically finasteride and minoxidil, being used by wealthy individuals to combat their genetic predisposition to baldness. It also discussed other potential treatments such as RU58841 and dutasteride.
New hair loss treatments include topical and gel formulations combining finasteride and dutasteride, with added caffeine and melatonin. The user reports positive results from using topical dutasteride.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.